- Home
- CTSO vs ESLA Comparison
CTSO vs ESLA Comparison
Compare CTSO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- ESLA
- Stock Information
- Founded
- CTSO 1997
- ESLA 2021
- Country
- CTSO United States
- ESLA United States
- Employees
- CTSO N/A
- ESLA N/A
- Industry
- CTSO Medical/Dental Instruments
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTSO Health Care
- ESLA Health Care
- Exchange
- CTSO Nasdaq
- ESLA Nasdaq
- Market Cap
- CTSO 58.6M
- ESLA 48.9M
- IPO Year
- CTSO N/A
- ESLA N/A
- Fundamental
- Price
- CTSO $0.92
- ESLA $1.68
- Analyst Decision
- CTSO Buy
- ESLA Strong Buy
- Analyst Count
- CTSO 2
- ESLA 1
- Target Price
- CTSO $5.50
- ESLA $16.00
- AVG Volume (30 Days)
- CTSO 78.2K
- ESLA 172.7K
- Earning Date
- CTSO 11-06-2025
- ESLA 11-20-2025
- Dividend Yield
- CTSO N/A
- ESLA N/A
- EPS Growth
- CTSO N/A
- ESLA N/A
- EPS
- CTSO N/A
- ESLA N/A
- Revenue
- CTSO $36,107,520.00
- ESLA N/A
- Revenue This Year
- CTSO $11.93
- ESLA N/A
- Revenue Next Year
- CTSO $21.22
- ESLA N/A
- P/E Ratio
- CTSO N/A
- ESLA N/A
- Revenue Growth
- CTSO 20.18
- ESLA N/A
- 52 Week Low
- CTSO $0.71
- ESLA $0.63
- 52 Week High
- CTSO $1.61
- ESLA $1.80
- Technical
- Relative Strength Index (RSI)
- CTSO 45.35
- ESLA 73.78
- Support Level
- CTSO $0.90
- ESLA $1.20
- Resistance Level
- CTSO $0.96
- ESLA $1.48
- Average True Range (ATR)
- CTSO 0.05
- ESLA 0.17
- MACD
- CTSO -0.00
- ESLA 0.03
- Stochastic Oscillator
- CTSO 16.67
- ESLA 85.27
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.